AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients. The company announced on Friday that the FDA had approved the ...

While immunotherapy has transformed the treatment ... At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab) as a combination regimen with its PARP ...

“Today’s approval for IMFINZI represents a paradigm shift, bringing the first perioperative immunotherapy to patients in the US with muscle-invasive bladder cancer and addressing a significant ...

Results showed the immunotherapy combination led to a 38 ... drug conjugate designed to target the cancer protein TROP2. —Imfinzi also added perioperative treatment of muscle invasive bladder ...

Brian’s insurer is Meritain Health, which is a subsidiary of industry giant Aetna. After Meritain rejected the initial ...

The approval of Imfinzi was granted based on results from ... 2 "With this approval, we can now offer immunotherapy treatment to people living with limited-stage small cell lung cancer, which ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as an ...

IMFINZI was generally well tolerated ... AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to ...